Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2023-01-31 / Expert Opin Drug Discov 2023 Jan;[Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-01-20 / Strahlenther Onkol 2023 Jan;Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-121Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-12-23 / Neuro Oncol 2022 Dec;Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-12-04 / Cancer Med 2023 Mar;12(6):7207-7221Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2022-09-06 / Molecules 2022 Sep;27(18)Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)Poster presentation at the International Symposium on Pediatric Neuro-Oncology
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de